Raymond James Financial Services Advisors, Inc. Genmab A/S Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$32.88 - $44.57 $202,770 - $274,863	-6,167 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$30.92 - $44.4 $12,739 - $18,292	-412 Reduced 6.26%	6,167 $202,000
Q4 2020 Feb 12, 2021	BUY	$33.66 - $40.76 $8,717 - $10,556	259 Added 4.1%	6,579 $268,000
Q3 2020 Nov 04, 2020	BUY	$33.07 - $38.68 $209,002 - $244,457	6,320 New	6,320 $231,000

Others Institutions Holding GMAB

# of Institutions

246

Shares Held

61.3M

Call Options Held

159K

Put Options Held

38K

Alliancebernstein L.P. New York, NY

14.9M
Shares

$328 Million
0.11% of portfolio
Black Rock Inc. New York, NY

5.08M
Shares

$112 Million
0.0% of portfolio
Ken Griffin Citadel Advisors LLC | Chicago, Il

3.09M
Shares

$67.9 Million
0.01% of portfolio
Orbis Allan Gray LTD Hamilton, D0

2.82M
Shares

$61.9 Million
0.4% of portfolio
Morgan Stanley New York, NY

2.81M
Shares

$61.6 Million
0.0% of portfolio

View Full List

About GENMAB A/S

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $14.5B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

More about GMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account